Cough syrup contaminated with DEG has caused ARI and the death of many children in The Gambia.

Published Date: 06 Mar 2023

USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...

Read Full News

Latest News

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Todays Updates

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

Latest News

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

News All Time

Closing the Gaps in CKD Screening, Transplant Access, and Education for Incarcerated Patients Laura Maursetter, MD

Laura J. Maursetter, MD, discusses the case for standardized kidney screening protocols, transplant access, and medical education reform for the correctional population.

Why IgA Nephropathy Risk Stratification Still Falls Short Ali Mehdi, MD, MEd

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD Alexander Combes, PhD

Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial Abigail Brooks, MA

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

New ESC, ERA Guideline Calls for Universal CKD Screening in Cardiovascular Disease Abigail Brooks, MA

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

Diagnosis to Data: What Patient Experience Adds to IgAN Research Bryon Wade

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.

Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data Alex Hillenbrand

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

FAQ: Understanding New ESC/ERA Guideline on Cardiovascular Disease and Chronic Kidney Disease Patrick Campbell

ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD Alexander Combes, PhD

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Inaxaplin Cuts Proteinuria in Broader APOL1 Kidney Disease Population Alex Hillenbrand

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD Abigail Brooks, MA

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

Recommended News For You

Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

Loneliness and social isolation linked to heightened risk of death in those with cancer

What Do Patients Want Doctors to Know About Breast Cancer Recurrence?

FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug

Medicaid expansion tied to smaller declines in early-stage cancer detection

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Recommended Articles For You

Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes 

Progressive Updates in Oncology for Healthcare Excellence 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In schizophrenia, sexual dysfunction is frequent.

2.

Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting

3.

Why breast cancer survivors don't take their medicine, and what can be done about it.

4.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

5.

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment

1.

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies

2.

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer

3.

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology

4.

Teaching Hematology Through Morphology-Based Learning

5.

Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

2.

How Iron Deficiency Can Affect Energy and Concentration

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

Blood Clotting Disorders Explained

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot